MedTrace Logo

Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects

NCT00627120 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-01-09

No results posted yet for this study

Summary

To assess the safety and tolerability of a single dose of VGX-1027 in the range of 1-800mg.

Conditions

  • Healthy

Interventions

DRUG

VGX-1027

Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.

Sponsors & Collaborators

  • GeneOne Life Science, Inc.

    collaborator INDUSTRY

  • VGX Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Stephan A Bart, MD · SNBL Clinical Pharmacology Center, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00627120 on ClinicalTrials.gov